Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens
Journal
Journal of Gynecologic Oncology
Journal Volume
29
Journal Issue
1
Date Issued
2018
Author(s)
Abstract
Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined. Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ?50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ?50 years of age in the CP group; and p=0.061 for patients ?50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050). Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age. ? 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Other Subjects
cyclophosphamide; paclitaxel; antineoplastic agent; paclitaxel; adult; age distribution; Article; cancer adjuvant therapy; cancer staging; cohort analysis; controlled study; disease free survival; female; high risk patient; human; major clinical study; middle aged; multiple cycle treatment; ovary carcinoma; overall survival; probability; retrospective study; Taiwan; treatment duration; treatment outcome; adjuvant chemotherapy; aged; cancer staging; epidemiology; mortality; ovariectomy; ovary tumor; pathology; survival analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Survival Analysis; Taiwan
Type
journal article